U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H11F6N7O
Molecular Weight 443.306
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SELINEXOR

SMILES

FC(F)(F)C1=CC(=CC(=C1)C2=NN(C=N2)\C=C/C(=O)NNC3=NC=CN=C3)C(F)(F)F

InChI

InChIKey=DEVSOMFAQLZNKR-RJRFIUFISA-N
InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-

HIDE SMILES / InChI
Selinexor (KPT-330) functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. Selinexor has been used in trials studying the treatment of acute myeloid leukaemia; chronic lymphocytic leukaemia, glioma, liposarcoma, among others.

CNS Activity

Curator's Comment: In clinical trials, the dose-limiting side effects of selinexor are central nervous system (CNS)-mediated anorexia with weight loss and malaise, as well as thrombocytopenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
680 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SELINEXOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5386 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SELINEXOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SELINEXOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SELINEXOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Other AEs: Thrombocytopenia, Thrombocytopenia...
Other AEs:
Thrombocytopenia (grade 4, 1%)
Thrombocytopenia (grade 3, 23%)
Thrombocytopenia (grade 1-2, 22%)
Hyponatremia (grade 4, 1%)
Hyponatremia (grade 3, 8%)
Hyponatremia (grade 1-2, 3%)
Nausea (grade 3, 12%)
Nausea (grade 1-2, 60%)
Fatigue (grade 3, 14%)
Fatigue (grade 1-2, 52%)
Decreased appetite (grade 3, 5%)
Decreased appetite (grade 1-2, 49%)
Vomiting (grade 3, 7%)
Vomiting (grade 1-2, 49%)
Weight loss (grade 1-2, 55%)
Anemia (grade 3, 11%)
Anemia (grade 1-2, 29%)
Dysgeusia (grade 1-2, 30%)
Blurred vision (grade 3, 1%)
Blurred vision (grade 1-2, 21%)
Diarrhea (grade 3, 1%)
Diarrhea (grade 1-2, 19%)
Constipation (grade 1-2, 8%)
Dizziness (grade 1-2, 14%)
Sources:
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Disc. AE: Diarrhea, Pyrexia...
Other AEs: Thrombocytopenia, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Diarrhea (grade 3, 3%)
Pyrexia (grade 3, 4%)
Other AEs:
Thrombocytopenia (grade 4, 15%)
Neutropenia (grade 4, 9%)
Anaemia (grade 4, 1%)
Fatigue (grade 3, 11%)
Hyponatraemia (grade 3, 8%)
Nausea (grade 3, 6%)
Dyspnoea (grade 4, 1%)
Acute respiratory distress syndrome (grade 5, 1 patient)
Cerebrovascular accident (grade 5, 1 patient)
Sepsis (grade 5, 3 patients)
Sources:
100 mg 2 times / week multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / week
Route: oral
Route: multiple
Dose: 100 mg, 2 times / week
Sources:
unhealthy
n = 92
Health Status: unhealthy
Population Size: 92
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness grade 1-2, 14%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Diarrhea grade 1-2, 19%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Blurred vision grade 1-2, 21%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Thrombocytopenia grade 1-2, 22%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Anemia grade 1-2, 29%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Hyponatremia grade 1-2, 3%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Dysgeusia grade 1-2, 30%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Decreased appetite grade 1-2, 49%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Vomiting grade 1-2, 49%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Fatigue grade 1-2, 52%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Weight loss grade 1-2, 55%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Nausea grade 1-2, 60%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Constipation grade 1-2, 8%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Blurred vision grade 3, 1%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Diarrhea grade 3, 1%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Anemia grade 3, 11%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Nausea grade 3, 12%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Fatigue grade 3, 14%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Thrombocytopenia grade 3, 23%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Decreased appetite grade 3, 5%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Vomiting grade 3, 7%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Hyponatremia grade 3, 8%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Hyponatremia grade 4, 1%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Thrombocytopenia grade 4, 1%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Fatigue grade 3, 11%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Diarrhea grade 3, 3%
Disc. AE
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Pyrexia grade 3, 4%
Disc. AE
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Nausea grade 3, 6%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Hyponatraemia grade 3, 8%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Anaemia grade 4, 1%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Dyspnoea grade 4, 1%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Thrombocytopenia grade 4, 15%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Neutropenia grade 4, 9%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Acute respiratory distress syndrome grade 5, 1 patient
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Cerebrovascular accident grade 5, 1 patient
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Sepsis grade 5, 3 patients
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
yes [IC50 6.2 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
yes
yes
Tox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
2013 Apr
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease.
2016 Dec 7
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
2016 May 1
Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
2017 Aug 29
Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells.
2017 Jun 13
Patents

Sample Use Guides

Ovarian, endometrial, or cervical carcinoma treatment: 50 mg/m2 twice weekly. Breast cancer oral 60 mg twice weekly.
Route of Administration: Oral
Growth of 14 T-ALL lines, which harbour different genetic aberrations, was dramatically reduced in response to treatment with KPT-330, with 50% inhibitory concentration (IC50) values of 34–203 nM after 72 h of exposure
Name Type Language
SELINEXOR
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
SELINEXOR [USAN]
Common Name English
(Z)-3-(3-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-1H-1,2,4-TRIAZOL-1-YL)-N'-(PYRAZIN-2-YL)ACRYLOHYDRAZIDE
Systematic Name English
selinexor [INN]
Common Name English
KPT-330
Code English
2-PROPENOIC ACID, 3-(3-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-1H-1,2,4-TRIAZOL-1-YL)-, 2-(2-PYRAZINYL)HYDRAZIDE, (2Z)-
Systematic Name English
SELINEXOR [MI]
Common Name English
Selinexor [WHO-DD]
Common Name English
XPOVIO
Brand Name English
SELINEXOR [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 880222
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
FDA ORPHAN DRUG 825721
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
NCI_THESAURUS C274
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
FDA ORPHAN DRUG 459014
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
FDA ORPHAN DRUG 527816
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
FDA ORPHAN DRUG 436414
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
EU-Orphan Drug EU/3/14/1355
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
FDA ORPHAN DRUG 432414
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
Code System Code Type Description
FDA UNII
31TZ62FO8F
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
EVMPD
SUB177942
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
CAS
1393477-72-9
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
SMS_ID
100000163576
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
DRUG BANK
DB11942
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
DAILYMED
31TZ62FO8F
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
PUBCHEM
71481097
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
EPA CompTox
DTXSID801026013
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
NCI_THESAURUS
C102546
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
LACTMED
Selinexor
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
DRUG CENTRAL
5330
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
MERCK INDEX
M12226
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
RXCUI
2178390
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
USAN
CD-85
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
WIKIPEDIA
Selinexor
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
INN
9872
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY
ChEMBL
CHEMBL3545185
Created by admin on Thu Jul 06 16:19:48 UTC 2023 , Edited by admin on Thu Jul 06 16:19:48 UTC 2023
PRIMARY